Skip to main content
Premium Trial:

Request an Annual Quote

Sirna to Manufacture Aptamers for Archemix

NEW YORK, July 28 (GenomeWeb News) - Sirna Therapeutics said this week that it has signed an exclusive, four-year deal to manufacture all of Archemix's aptamers used through phase IIa clinical development. Sirna has additionally granted a worldwide, non-exclusive, perpetual license to its aptamer manufacture and commercialization intellectual property to Archemix.


The arrangement, said Sirna, follows an October 2003 deal under which Sirna manufactured Archemix's anti-thrombin aptamer, ARC183, for development up through phase IIa testing.


"Sirna's mission is to develop nucleic acid therapeutics based on RNA interference," Sirna senior vice president and COO Nassim Usman said in a statement. "Through our partnership and licensing agreement with Archemix ... Sirna will generate revenues as Archemix develops and commercializes its aptamer products."

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.